Cardiac telerehabilitation with long-term follow-up reduces GlycA and improves lipoprotein particle profile: A randomised controlled trial
Ernesto Dalli-Peydró, Rafael Gisbert-Criado, Nuria Amigó, Nuria Sanz-Sevilla, Juan Cosín-Sales, Ernesto Dalli-Peydró, Rafael Gisbert-Criado, Nuria Amigó, Nuria Sanz-Sevilla, Juan Cosín-Sales
Abstract
Background: A 10-month strategy of cardiac telerehabilitation (CTR) improved outcomes over a standard centre-based cardiac rehabilitation (CBCR), as recently published. We hypothesised that prolonged telerehabilitation could also improve proinflammatory status and lipoprotein particle composition.
Methods: A randomised controlled trial compared a prolonged CTR program with CBCR in post-ACS patients. Patient's age was 18-72 years with low-risk criteria. Blood samples were drawn at baseline, at 4- and 10-months follow-up. Advanced lipoprotein characterization was performed using the NMR-based Liposcale test. Signals from glycoproteins (GlycA and GlycB) were also assessed.
Results: The final analysis included 31 patients in the CTR group and 25 patients in the CBCR group. GlycA decreased in the CTR group (p = 0,007). LDL particle number (LDL-P) increase in both groups, but it was at the expense of small-sized LDL in the CBCR group (p = 0.012). Triglycerides in intermediate-density lipoprotein (IDL-TG) increased only in the CBCR group (p = 0.043). The triglyceride-to-HDL (TG/HDL) ratio decreased only in the CTR group (p = 0.006). The TG/HDL ratio was correlated with GlycA (Spearman's correlation coefficient: 0.558, p < 0.001) but not with CRP (p = 0.101).
Conclusions: Our results showed that a 10-month CTR program reduced GlycA levels, the TG/HDL ratio and avoided unfavourable long-term changes in lipoprotein particle composition. Registration at http://ClinicalTrials.gov. NCT number: 04942977.
Keywords: Cardiac rehabilitation; Coronary heart disease; Glycoproteins; Lipoprotein particles; Mobile health; Telerehabilitation.
Conflict of interest statement
Declaration of Competing Interest Nuria Amigó has a patent (“Method for lipoprotein characterization”) issued and is the stoke owner of Biosfer Teslab, the company that analyses the metabolites reported in the manuscript. The other authors declare no conflicts of interest. The funders had no role in the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.
Source: PubMed